Live Breaking News & Updates on Mass Of Body Structure
Stay updated with breaking news from Mass of body structure. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
email article Adding the immune checkpoint inhibitor nivolumab (Opdivo) to neoadjuvant chemotherapy dramatically increased pathologic complete response (pCR) in patients with operable lung cancer, a randomized trial showed. The pCR rate increased from 2.2% with chemotherapy alone to 24.0% with the addition of nivolumab. The between-group difference increased in an analysis limited to patients who had complete resection. Clearance of circulating tumor (ct) DNA during neoadjuvant therapy increased the likelihood of pCR, reported Patrick M. Forde, MD, of the Johns Hopkins Sidney Kimmel Cancer Center in Baltimore, at the American Association for Cancer Research (AACR) virtual meeting. CheckMate 816 showed a statistically significant improvement in pCR, said Forde. This benefit was consistent across disease stages, histology, TMB (tumor mutational burden) and PD-L1 expression. The study continues to mature for the event-free survival (EFS) primary endpoint. ....
email article Dual checkpoint blockade with nivolumab (Opdivo) plus ipilimumab (Yervoy) failed to improve outcomes as adjuvant therapy for resected melanoma over nivolumab alone, the CheckMate 915 trial found. In the intent-to-treat (ITT) population of more than 1,800 patients with stage IIIB-D/IV melanoma, relapse-free survival (RFS) at 2 years was nearly identical with the combination versus single-agent PD-1 blockade with nivolumab, at 64.6% and 63.2%, respectively (HR 0.92, 95% CI 0.77-1.09), reported Georgina Long, MBBS, PhD, of the University of Sydney. In the subset with low PD-L1 expression ( ....
email article Use of antihypertensive drugs had no consistent association with cancer risk, according to a review of 33 clinical studies. Patients treated with any of five different classes of antihypertensive drugs had essentially the same cancer risk as that of placebo-treated patients. Comparisons of each antihypertensive class against all the others showed no association with an increased risk of cancer, with the exception of calcium channel blockers (CCBs), which had only a modestly higher risk versus the other drug classes (HR 1.06, 95% CI 1.01-1.11). Though reassuring, the data do not close the door on the issue, as some comparisons had insufficient data to rule out the possibility of excess cancer risk, reported Kazem Rahimi, DM, of the University of Oxford in England, and colleagues in ....
Note that some links may require registration or subscription. One of Johnson & Johnson s contract vaccine manufacturers messed up during production of 15 million doses, putting shipments behind schedule. ( New York Times) Meanwhile, Pfizer and BioNTech said their vaccine was 100% effective in South Africa, where the troubling B.1.351 variant is widespread, amidst other boasts about the product. France will undergo a third national lockdown through the end of April due to accelerating coronavirus spread. ( NPR) As of Thursday at 8:00 a.m. EDT, the unofficial COVID-19 toll reached 30,461,066 cases and 552,073 deaths reflecting increases of 66,878 and 1,075, respectively, over the previous 24 hours. In 2020, COVID-19 was the third leading cause of death in the U.S., according to the CDC; during some weeks, it was responsible for one-quarter of all deaths. ....
Rutgers Robert Wood Johnson Medical School, Gastroenterology) University of Gothenburg, PLOS One) The FDA and its European counterpart have agreed on a template for streamlining development and approval of new drugs for pediatric cancers. ( Endpoints News) Bristol Myers Squibb announced that a phase III trial of the anti-LAG-3 antibody relatlimab plus nivolumab (Opdivo) met the primary endpoint of improved progression-free survival in patients with previously untreated unresectable or metastatic melanoma. Overall survival and progression-free survival improved significantly in patients with metastatic hormone receptor-positive, HER2-negative breast cancer treated with frontline palbociclib (Ibrance) and letrozole, according to a statement from Pfizer. ....